References
Key articles
Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol. 2012 Jul;67(1):1.e1-16. Abstract
Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era. Part II. Molecular aspects and clinical management. J Am Acad Dermatol. 2012 Jul;67(1):19.e1-12. Abstract
Wernli KJ, Henrikson NB, Morrison CC, et al. Screening for skin cancer in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016 Jul 26;316(4):436-47.Full text Abstract
Reference articles
1. McKee PH, Calonje E, Granter SR, eds. Pathology of the skin. 3rd ed. London: Elsevier; 2005.
2. Argenziano G, Zalaudek I, Ferrara G, et al. Proposal of a new classification system for melanocytic naevi. Br J Dermatol. 2007 Aug;157(2):217-27. Abstract
3. Schmoeckel, C. Classification of melanocytic nevi: do nodular and flat nevi develop differently? Am J Dermatopathol. 1997 Feb;19(1):31-4. Abstract
4. Burkhart CG. Dysplastic nevi. N Engl J Med. 2004 Mar 18;350(12):1258-9. Abstract
5. Bolognia JL, Jorizzo JL, Rapini RP, et al. Dermatology. 2nd ed. New York, NY: Mosby; 2008.
6. Tannous ZS, Mihm MC Jr, Sober AJ, et al. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol. 2005 Feb;52(2):197-203. Abstract
7. Schaffer JV. Pigmented lesions in children: when to worry. Curr Opin Pediatr. 2007 Aug;19(4):430-40. Abstract
8. Elder DE, Massi D, Scolyer RA, et al, eds. WHO classification of skin tumours. 4th ed. Lyon, France: International Agency for Research on Cancer; 2018.
9. Mesbah Ardakani N. Dysplastic/Clark naevus in the era of molecular pathology. Australas J Dermatol. 2019 Aug;60(3):186-91. Abstract
10. Sarin KY, Sun BK, Bangs CD, et al. Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatol. 2013 Sep;149(9):1077-81.Full text Abstract
11. Elder DE, Bastian BC, Cree IA, et al. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med. 2020 Apr;144(4):500-22.Full text Abstract
12. Dulon M, Weichenthal M, Blettner M, et al. Sun exposure and number of nevi in 5- to 6- year-old European children. J Clin Epidemiol. 2002 Nov;55(11):1075-81. Abstract
13. Maize JC, Foster G. Age-related changes in melanocytic naevi. Clin Exp Dermatol. 1979 Mar;4(1):49-58. Abstract
14. Coleman WP 3rd, Gately LE 3rd, Krementz AB, et al. Nevi, lentigines, and melanoma in blacks. Arch Dermatol. 1980 May;116(5):548-51. Abstract
15. Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: a randomized controlled trial. JAMA. 2000 Jun 14;283(22):2955-60.Full text Abstract
16. Warner PM, Yakuboff KP, Kagan RJ, et al. An 18-year experience in the management of congenital nevomelanocytic nevi. Ann Plast Surg. 2008 Mar;60(3):283-7. Abstract
17. Ackerman AB. "Dysplastic nevus" syndrome: does a survey make it real? J Am Acad Dermatol. 2003 Mar;48(3):461-3. Abstract
18. Valiukeviciene S, Miseviciene I, Gollnick H. The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol. 2005 May;141(5):579-86. Abstract
19. Wachsmuth RC, Turner F, Barrett JH, et al. The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol. 2005 Jan;124(1):56-62. Abstract
20. Rivers JK, Maclennan R, Kelly JW, et al. The eastern Australian childhood nevus study: prevalence of atypical nevi, congenital nevus-like nevi, and other pigmented lesions. J Am Acad Dermatol. 1995 Jun;32(6):957-63. Abstract
21. Gallagher RP, McLean DI. The epidemiology of acquired melanocytic nevi: a brief review. Dermatol Clin. 1995 Jul;13(3):595-603. Abstract
22. Grichnik JM. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol. 2008 Oct;128(10):2365-80. Abstract
23. Burkhart CG, Burkhart CN. The mole theory: primary function of melanocytes and melanin may be antimicrobial defense and immunomodulation (not solar protection). Int J Dermatol. 2005 Apr;44(4):340-2. Abstract
24. Koh HK. Cutaneous melanoma. N Engl J Med. 1991 Jul 18;325(3):171-82. Abstract
25. Harrison SL, MacLennan R, Buettner PG. Sun exposure and the incidence of melanocytic nevi in young Australian children. Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2318-24. Abstract
26. Kelly JW, Rivers JK, MacLennan R, et al. Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol. 1994 Jan;30(1):40-8. Abstract
27. American Academy of Dermatology. Body mole map. 2022 [internet publication].Full text
28. American Melanoma Foundation. ABCD's of melanoma. 2006 [internet publication].Full text
29. Schaffer JV, Orlow SJ, Lazova R, et al. Speckled lentiginous nevus: within the spectrum of congenital melanocytic nevi. Arch Dermatol. 2001 Feb;137(2):172-8.Full text Abstract
30. Cyr PR. Atypical moles. Am Fam Physician. 2008 Sep 15;78(6):735-40. Abstract
31. Larsen F, Cockerell CJ. The dysplastic nevus concept. Pathology Case Rev. 2007 Nov/Dec;12(6):240-4.
32. Salopek TG. The dilemma of the dysplastic nevus. Dermatol Clin. 2002 Oct;20(4):617-28. Abstract
33. Grob JJ, Bonerandi JJ. The ugly duckling sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998 Jan;134(1):103-4. Abstract
34. Zhang AJ, Rush PS, Tsao H, et al. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol. 2019 Dec;46(12):965-72.Full text Abstract
35. Yeh I, Lang UE, Durieux E, et al. Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Commun. 2017 Sep 21;8(1):644.Full text Abstract
36. Mandal RV, Murali R, Lundquist KF, et al. Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up. Am J Surg Pathol. 2009 Dec;33(12):1778-82. Abstract
37. Campos-do-Carmo G, Ramos-e-Silva M. Dermatoscopy: basic concepts. Int J Dermatol. 2008 Jul;47(7):712-9. Abstract
38. Tschandl P, Rosendahl C, Kittler H. The HAM10000 dataset, a large collection of multi-source dermatoscopic images of common pigmented skin lesions. Sci Data. 2018 Aug 14;5:180161.Full text Abstract
39. Smith L, Macneil S. State of the art in non-invasive imaging of cutaneous melanoma. Skin Res Technol. 2011 Aug;17(3):257-69.Full text Abstract
40. Brehmer F, Ulrich M, Haenssle HA. Strategies for early recognition of cutaneous melanoma - present and future. Dermatol Pract Conc. 2012 Jul 31;2(3):203a06.Full text Abstract
41. Walter FM, Morris HC, Humphrys E, et al. Protocol for the MoleMate UK Trial: a randomised controlled trial of the MoleMate system in the management of pigmented skin lesions in primary care [ISRCTN 79932379]. BMC Fam Pract. 2010 May 11;11:36.Full text Abstract
42. Moncrieff M, Cotton S, Claridge E, et al. Spectrophotometric intracutaenous analysis: a new technique for imagining pigmented skin lesions. Br J Dermatol. 2002 Mar;146(3):448-57. Abstract
43. Mackie RM, Doherty VR. Seven-point checklist for melanoma. Clin Exp Dermatol. 1991 Mar;16(2):151-3. Abstract
44. Walter FM, Morris HC, Humphrys E, et al. Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ. 2012 Jul 4;345:e4110.Full text Abstract
45. Elbaum M, Kopf AW, Rabinovitz HS, et al. Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol. 2001 Feb;44(2):207-18. Abstract
46. Bolognia JL. Biopsy techniques for pigmented lesions. Dermatol Surg. 2000 Jan;26(1):89-90. Abstract
47. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol. 2012 Jul;67(1):1.e1-16. Abstract
48. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era. Part II. Molecular aspects and clinical management. J Am Acad Dermatol. 2012 Jul;67(1):19.e1-12. Abstract
49. Arneja JS, Gosain AK. Giant congenital melanocytic nevi. Plast Reconstr Surg. 2009 Jul;124(1 Suppl):1e-13e. Abstract
50. Marghoob AA, Kopf AW. Persistent nevus: an exception to the ABCD rule of dermoscopy. J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):474-5. Abstract
51. Kornber R, Ackerman AB. Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. Arch Dermatol. 1975 Dec;111(12):1588-90. Abstract
52. New Zealand Guidelines Group. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Jun 2008 [internet publication].Full text
53. Strazzula L, Vedak P, Hoang MP, et al. The utility of re-excising mildly and moderately dysplastic nevi: a retrospective analysis. J Am Acad Dermatol. 2014 Dec;71(6):1071-6. Abstract
54. Reddy KK, Farber MJ, Bhawan J, et al. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol. 2013 Aug;149(8):928-34.Full text Abstract
55. Abello-Poblete MV, Correa-Selm LM, Giambrone D, et al. Histologic outcomes of excised moderate and severe dysplastic nevi. Dermatol Surg. 2014 Jan;40(1):40-5. Abstract
56. Kim CC, Berry EG, Marchetti MA, et al. Risk of subsequent cutaneous melanoma in moderately dysplastic nevi excisionally biopsied but with positive histologic margins. JAMA Dermatol. 2018 Dec 1;154(12):1401-8.Full text Abstract
57. Kim CC, Swetter SM, Curiel-Lewandrowski C, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol. 2015 Feb;151(2):212-8. Abstract
58. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017 Jun 28;357:j2813.Full text Abstract
59. Ferris LK, Jansen B, Ho J, et al. Utility of a noninvasive 2-gene molecular assay for cutaneous melanoma and effect on the decision to biopsy. JAMA Dermatol. 2017 Jul 1;153(7):675-80.Full text Abstract
60. Ko JS, Matharoo-Ball B, Billings SD, et al. Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes. Cancer Epidemiol Biomarkers Prev. 2017 Apr 4;26(7):1107-13.Full text Abstract
61. Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol. 2013 May;37(5):676-84. Abstract
62. Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol. 2012 Jun;36(6):808-17. Abstract
63. Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018 Nov;42(11):1456-65.Full text Abstract
64. Colebatch AJ, Ferguson P, Newell F, et al. Molecular genomic profiling of melanocytic nevi. J Invest Dermatol. 2019 Aug;139(8):1762-8.Full text Abstract
65. Ostendorf W. Preparation for safe medication administration. In: Perry AG, Potter PA, Elkin MK, eds. Nursing interventions & clinical skills. 7th ed. St Louis, MO: Mosby; 2020.
66. WHO Best Practices for Injections and Related Procedures Toolkit. Geneva: World Health Organization; 2010 Mar. Abstract
67. Jin JF, Zhu LL, Chen M, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923-42.Full text Abstract
68. Tanaka M. Dermoscopy. J Dermatol. 2006 Aug;33(8):513-7. Abstract
69. Zalaudek I, Docimo G, Argenziano G. Using dermoscopic criteria and patient-related factors for the management of pigmented melanocytic nevi. Arch Dermatol.2009 Jul;145(7):816-26.Full text Abstract
70. American Cancer Society. Cancer facts and figures 2022. 2022 [internet publication].Full text
71. Rigel DS. Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32. Abstract
72. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010 Feb;3(2):233-45. Abstract
73. US Preventive Services Task Force. Skin cancer prevention: behavioral counseling. Mar 2018 [internet publication].Full text
74. US Preventive Services Task Force. Final recommendation statement. Skin cancer: screening. Apr 2023 [internet publication].Full text Abstract
75. Smack DP, Harrington AC, Dunn C, et al. Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment. A randomized controlled trial. JAMA. 1996 Sep 25;276(12):972-7. Abstract
76. Campbell RM, Perlis CS, Fisher E, et al. Gentamicin ointment versus petrolatum for management of auricular wounds. Dermatol Surg. 2005 Jun;31(6):664-9. Abstract
77. Gette MT, Marks JG Jr, Maloney ME. Frequency of postoperative allergic contact dermatitis to topical antibiotics. Arch Dermatol. 1992 Mar;128(3):365-7. Abstract
78. Suzuki H, Anderson RR. Treatment of melanocytic nevi. Dermatol Ther. 2005 May-Jun;18(3):217-26. Abstract
79. Polder KD, Landau JM, Vergilis-Kalner IJ, et al. Laser eradication of pigmented lesions: a review. Dermatol Surg. 2011 May;37(5):572-95. Abstract
80. Lee PK, Rosenberg CN, Tsao H, et al. Failure of Q-switched ruby laser to eradicate atypical-appearing solar lentigo: report of two cases. J Am Acad Dermatol. 1998 Feb;38(2 Pt 2):314-7. Abstract
81. Gottschaller C, Hohenleutner U, Landthaler M. Metastasis of a malignant melanoma 2 years after carbon dioxide laser treatment of a pigmented lesion: case report and review of the literature. Acta Derm Venereol. 2006;86(1):44-7.Full text Abstract
82. Woodrow SL, Burrows SN. Malignant melanoma occurring at the periphery of a giant congenital naevus preciously treated with laser therapy. Br J Dermatol. 2003 Oct;149(4):886-8. Abstract
83. Dummer R, Kempf W, Burg G. Pseudo-melanoma after laser therapy. Dermatology. 1998;197(1):71-3. Abstract
84. Elder DE, Elenitsas R, Johnson BL, eds. Lever's histopathology of the skin. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2009.
85. Herzog C, Pappo A, Bondy M, et al. Malignant melanoma. In: Bleyer A, O'Leary M, Barr R, et al, eds. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006:53-64.Full text
86. Vourc'h-Jourdain M, Martin L, Barbarot S; aRED. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol. 2013 Mar;68(3):493-8.e1-14. Abstract
87. Barnhill RL, Flotte TJ, Fleischli M, et al. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer. 1995 Nov 15;76(10):1833-45. Abstract
88. Cerrato F, Wallins JS, Webb ML, et al. Outcomes in pediatric atypical Spitz tumors treated without sentinel lymph node biopsy. Pediatr Dermatol. 2011 Dec 30;29(4):448-53. Abstract
89. Lee CY, Sholl LM, Zhang B, et al. Atypical spitzoid neoplasms in childhood: a molecular and outcome study. Am J Dermatopathol. 2017 Mar;39(3):181-6. Abstract
90. Massi D, Tomasini C, Senetta R, et al. Atypical Spitz tumors in patients younger than 18 years. J Am Acad Dermatol. 2014 Oct 25;72(1):37-46. Abstract
91. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol. 2001 Aug;45(2):260-76. Abstract
92. Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions: 'the B-K mole syndrome'. Arch Dermatol. 1978 May;114(5):732-8. Abstract
93. Tsao H, Sober AJ, Niendorf KB, et al. Case records of the Massachusetts General Hospital: a 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med. 2004 Feb 26;350(9):924-32. Abstract
94. de Maleissye MF, Beauchet A, Saiag P, et al. Sunscreen use and melanocytic nevi in children: a systematic review. Pediatr Dermatol. 2013 Jan-Feb;30(1):51-9. Abstract
95. Crane LA, Deas A, Mokrohisky ST, et al. A randomized intervention study of sun protection promotion in well-child care. Prev Med. 2006 Mar;42(3):162-70. Abstract
96. Menzies SW. Is sun exposure a major cause of melanoma? Yes. BMJ. 2008 Jul 22;337:a763. Abstract
97. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations - US surveillance, epidemiology, and end results (SEER) program, 1992 to 2001. Arch Dermatol. 2005 Apr;141(4):477-81.Full text Abstract
98. Shuster S. Is sun exposure a major cause of melanoma? No. BMJ. 2008 Jul 22;337:a764. Abstract
Use of this content is subject to our disclaimer